CERo Therapeutics Inc. (CERO)
NASDAQ: CERO
· Real-Time Price · USD
7.97
-0.14 (-1.73%)
At close: Aug 15, 2025, 3:59 PM
7.89
-1.07%
After-hours: Aug 15, 2025, 07:49 PM EDT
CERo Therapeutics Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q2 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Jun 30, 2021 |
Net Income | -5.11M | -1.05M | -1.49M | -2.45M | -2.3M | -282.76K | -334.03K | -2.09M | -2.44M | -262.68K | 84.5K | -111.57K | -378K | -314.55K | n/a |
Depreciation & Amortization | 269.48K | 284.63K | 297.34K | 293.25K | 288.16K | n/a | n/a | 277.45K | 273.58K | n/a | n/a | n/a | n/a | n/a | n/a |
Stock-Based Compensation | 304.95K | -1.4M | 404.20 | 1.4K | 100.72 | n/a | 23.5K | 27.28K | 28.14K | n/a | n/a | n/a | n/a | n/a | n/a |
Other Working Capital | n/a | -669.43K | -27.66K | 841.41K | -618.88K | 207.14K | 199.43K | 108.78K | 185.59K | 1.45M | 662.34K | 139.87K | 96.69K | -366.08K | n/a |
Other Non-Cash Items | n/a | 5.62M | 542.87K | -1.96M | -2.16M | -110.99K | -121.52K | 445.86K | 514.33K | -1.56M | -981.65K | -265.01K | -26.78K | -16.48K | n/a |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Change in Working Capital | n/a | 691.72K | -627.76K | 576.39K | -905.37K | 207.14K | 199.43K | -35.5K | 663.27K | 1.45M | 722.8K | 139.87K | 96.69K | -366.08K | n/a |
Operating Cash Flow | -4.45M | 4.15M | -2.76K | -3.54M | -5.08M | -186.61K | -256.12K | -2.07M | -1.44M | -373.1K | -174.35K | -236.71K | -308.09K | -697.11K | n/a |
Capital Expenditures | n/a | -4 | n/a | n/a | -2 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | n/a | n/a | n/a | n/a | n/a | -13.89M | n/a | n/a | n/a | -325K | n/a | n/a | n/a | -178.5M | n/a |
Sales Maturities Of Investments | n/a | n/a | n/a | n/a | n/a | n/a | 5.08M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | n/a | n/a | n/a | n/a | n/a | 73.31K | 678.99K | 285.24K | n/a | 181.04M | 128.49K | n/a | n/a | n/a | n/a |
Investing Cash Flow | n/a | -4 | -185.24K | n/a | n/a | -13.82M | 5.69M | 285.24K | n/a | 180.71M | 128.49K | n/a | n/a | -178.5M | n/a |
Debt Repayment | n/a | 19.71K | -150.9K | -149.34K | -19.71K | n/a | n/a | 605.23K | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | -27.84M | -5.64M | n/a | n/a | -139.35M | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | 5.61M | -9.2M | 2.49K | 2.59K | 13.73K | 160K | 220K | -38.72K | 5.17K | 650.88K | n/a | n/a | n/a | 180.3M | n/a |
Financial Cash Flow | 6.32M | -9.18M | 2.49M | 2.59M | 7.16M | -27.68K | -5.42M | 566.51K | 5.17K | -138.7M | n/a | n/a | n/a | 180.3M | n/a |
Net Cash Flow | 1.88M | -960.77K | 2.46M | -946.08K | 4.5M | -960.77K | -1.32M | -1.51M | -1.43M | 41.63M | -45.86K | -236.71K | -308.09K | 1.1M | n/a |
Free Cash Flow | -4.45M | 4.15M | -1.32M | -3.54M | -5.08M | -186.61K | -256.12K | -2.07M | -1.44M | -373.1K | -174.35K | -236.71K | -308.09K | -697.11K | n/a |